Fecal microbiota transplantation (FMT) has been recognized as a promising treatment for dysbiosis-related diseases. Since 2014, FMT has been utilized to treat ulcerative colitis (UC) in our clinical studies and has shown efficacy and safety. As donor screening (DS) is the primary step to ensure the safety of FMT, we report our experience with DS and present the screening results to improve the prospective DS criteria and provide references for future studies. The donor candidates were screened according to the DS criteria. The first DS criteria were proposed in June 2014 and revised substantially in May 2018. We further sorted the screening results and costs of laboratory tests. From June 2014 to April 2018, the DS eligibility rate was 50%. The total laboratory testing cost for each candidate was JPY 17,580/USD 160.21. From May 2018 to September 2021, the DS eligibility rate was 25.6%. The total laboratory testing cost for each candidate was JPY 40,740/USD 371.36. The reduction in donor eligibility rates due to more stringent criteria should be considered for cost and safety. Studies must consider the latest updates and make timely modifications in the DS criteria to ensure patient safety.
Artemisinin-resistant Plasmodium falciparum is spreading in Southeast Asia and Africa. In vivo susceptibility to artemisinin is studied by looking at the rate of decline of peripheral parasitemia (parasite clearance half-life). However, parasites that are adhered/sequestered to the endothelium and undetectable in the peripheral blood are not considered in the estimation of parasite clearance. Here we evaluated the influence of sequestration on in vivo artemisinin efficacy in Uganda, where artemisinin resistance is spreading. We analyzed 133 P. falciparum malaria patients included in an in vivo study on artemisinin efficacy in northern Uganda in 2018 and 2019. The parasite clearance half-life was estimated from peripheral parasitemia after artemisinin monotherapy. P. falciparum histidine-rich protein 2 (PfHRP2) was measured in pre-treatment plasma. The number of sequestered parasites was estimated from PfHRP2 concentration and peripheral parasitemia. The estimated number of sequestered parasites per plasma volume ranged from 0 to 2,564,000/μL. Inflammation, thrombocytopenia, and dyslipidemia were significantly associated with sequestration independently of peripheral parasitemia. The median parasite clearance half-lives were 1.65 h in patients infected with Pfkelch13 wild-type parasites (N = 104) and 3.95 h in those with A675V artemisinin-resistant mutant (N = 18). In the multivariable model for the wild-type population, 1,000,000/μL of sequestered parasites were estimated to delay parasite clearance by 16.8% (95% CI: 5.1%–28.5%) although it was not clear in the A675V population. In P. falciparum malaria patients without artemisinin-resistant mutations, intensive sequestration delays parasite clearance after treatment, which may contribute to reduced artemisinin efficacy.
25 April 2024 in Journal of Antimicrobial Chemotherapy
Artemisinin-resistant Plasmodium falciparum malaria is currently spreading globally, including in Africa. Artemisinin resistance also leads to resistance to partner drugs used in artemisinin-based combination therapies. Sequencing of kelch13, which is associated with artemisinin resistance, culture-based partner drug susceptibility tests, and ELISA-based growth measurement are conventionally used to monitor resistance; however, their application is challenging in resource-limited settings. An experimental package for field studies with minimum human/material requirements was developed. First, qPCR-based SNP assay was applied in artemisinin resistance screening, which can detect mutations within 1 h and facilitate sample selection for subsequent processes. It had 100% sensitivity and specificity compared with DNA sequencing in the detection of the two common artemisinin resistance mutations in Uganda, C469Y and A675V. Moreover, in the partner drug susceptibility test, the cultured samples were dry-preserved on a 96-well filter paper plate and shipped to the central laboratory. Parasite growth was measured by ELISA using redissolved samples. It well reproduced the results of direct ELISA, reducing significant workload in the field (Pearson correlation coefficient: 0.984; 95% CI: 0.975–0.990). Large-scale and sustainable monitoring is required urgently to track rapidly spreading drug-resistant malaria. In malaria-endemic areas, where research resources are often limited, simplicity and feasibility of the procedure is especially important. Our approach combines a qPCR-based rapid test, which is also applicable to point-of-care diagnosis of artemisinin resistance and centralized analysis of ex vivo culture. The approach could improve efficiency of field experiments and accelerate global drug resistance surveillance.
Uganda is listed among the few African countries where artemisinin partial resistance has already emerged. It has been increasing there since 2017, providi
30 September 2026 in The Journal of Infectious Diseases
Background: Artemisinin (ART) partial resistance has been reported in Southeast Asia and East Africa, but its population-level phenotypic dynamics remain poorly understood. We aimed to evaluate population-level changes in ART susceptibility in Plasmodium falciparum in Northern Uganda using an ex vivo quantitative ring-stage survival assay (qRSA), which assesses parasite survival across 7 serial dihydroartemisinin (DHA) concentrations. Methods: We conducted repeated cross-sectional surveys in 2014, 2015, 2022, and 2024 in Gulu, Northern Uganda. Ex vivo qRSA was used to compare parasite survival across DHA concentrations before and after the known emergence of ART partial resistance. qRSA resistance level was operationally defined as the highest DHA concentration at which the survival rate (SR) was ≥1%. Results: A total of 323 participants with uncomplicated symptomatic P. falciparum monoinfection were enrolled. qRSA data were obtained from 156 samples. After the known emergence of ART partial resistance, low-level parasite survival persisted toward progressively higher DHA concentrations, resulting in a shift toward higher qRSA resistance levels. All pure kelch13 A675V isolates were classified at the highest qRSA resistance level (700 nM), whereas pure C469Y isolates were distributed across qRSA resistance levels from 87.5 to 700 nM. A similar, but less robust, shift was observed among kelch13 wild-type isolates, accompanied by increased SRs, particularly at 700 nM. Conclusions: These findings suggest that the population-level shift in ART susceptibility was characterized by persistence of low-level survival toward higher DHA concentrations. Multiconcentration RSA may provide additional insights into early changes in ART susceptibility that are not captured by conventional binary resistance classifications.